Anacor Pharmaceuticals Inc. Hits New 52-Week High at $14.39 (ANAC)
Shares of Anacor Pharmaceuticals (NASDAQ:ANAC) hit a new 52-week high on Monday, American Banking News.com reports. The company traded as high as $14.39 and last traded at $13.90, with a volume of 694,075 shares trading hands. The stock had previously closed at $13.83.
Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of Anacor Pharmaceuticals from $13.00 to $17.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Wedbush raised their price target on shares of Anacor Pharmaceuticals from $20.00 to $29.00 in a research note to investors on Friday. Finally, analysts at Deutsche Bank raised their price target on shares of Anacor Pharmaceuticals from $11.00 to $20.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Anacor Pharmaceuticals has a 1-year low of $3.00 and a 1-year high of $14.10. The stock has a 50-day moving average of $10.78 and a 200-day moving average of $7.80. The company’s market cap is $560.9 million.
Anacor Pharmaceuticals (NASDAQ:ANAC) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.03. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. The company’s quarterly revenue was up 30.8% on a year-over-year basis. On average, analysts predict that Anacor Pharmaceuticals will post $-0.98 earnings per share for the current fiscal year.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.